<table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 3: Active Metabolite Pharmacokinetics and Antiplatelet Responses by CYP2C19 Metabolizer Status</caption>
<col></col>
<col></col>
<col></col>
<col></col>
<col></col>
<col></col>
<thead>
<tr>
<th valign="top"></th>
<th valign="top"> Dose</th>
<th align="center" valign="top"> Ultrarapid <br/>(n=10)</th>
<th align="center" valign="top"> Extensive <br/>(n=10)</th>
<th align="center" valign="top"> Intermediate <br/>(n=10)</th>
<th align="center" valign="top"> Poor <br/>(n=10)</th>
</tr>
</thead>
<tfoot>
<tr>
<td colspan="6" valign="top"> Values are mean (SD)</td>
</tr>
</tfoot>
<tbody>
<tr>
<td valign="top"> Cmax (ng/mL)</td>
<td valign="top"> 300 mg (24 h)</td>
<td align="center" valign="top"> 24 (10)</td>
<td align="center" valign="top"> 32 (21)</td>
<td align="center" valign="top"> 23 (11)</td>
<td align="center" valign="top"> 11 (4)</td>
</tr>
<tr>
<td valign="top"> </td>
<td valign="top"> 600 mg (24 h)</td>
<td align="center" valign="top"> 36 (13)</td>
<td align="center" valign="top"> 44 (27)</td>
<td align="center" valign="top"> 39 (23)</td>
<td align="center" valign="top"> 17 (6)</td>
</tr>
<tr>
<td valign="top"> </td>
<td valign="top"> 75 mg (Day 5)</td>
<td align="center" valign="top"> 12 (6)</td>
<td align="center" valign="top"> 13 (7)</td>
<td align="center" valign="top"> 12 (5)</td>
<td align="center" valign="top"> 4 (1)</td>
</tr>
<tr>
<td valign="top"> </td>
<td valign="top"> 150 mg (Day 5)</td>
<td align="center" valign="top"> 16 (9)</td>
<td align="center" valign="top"> 19 (5)</td>
<td align="center" valign="top"> 18 (7)</td>
<td align="center" valign="top"> 7 (2)</td>
</tr>
<tr>
<td valign="top"> IPA (%)<footnote id="FOOT_7367">Inhibition of platelet aggregation with 5mcM ADP; larger value indicates greater platelet inhibition</footnote>
</td>
<td valign="top"> 300 mg (24 h)</td>
<td align="center" valign="top"> 40 (21)</td>
<td align="center" valign="top"> 39 (28)</td>
<td align="center" valign="top"> 37 (21)</td>
<td align="center" valign="top"> 24 (26)</td>
</tr>
<tr>
<td valign="top"> </td>
<td valign="top"> 600 mg (24 h)</td>
<td align="center" valign="top"> 51 (28)</td>
<td align="center" valign="top"> 49 (23)</td>
<td align="center" valign="top"> 56 (22)</td>
<td align="center" valign="top"> 32 (25)</td>
</tr>
<tr>
<td valign="top"> </td>
<td valign="top"> 75 mg (Day 5)</td>
<td align="center" valign="top"> 56 (13)</td>
<td align="center" valign="top"> 58 (19)</td>
<td align="center" valign="top"> 60 (18)</td>
<td align="center" valign="top"> 37 (23)</td>
</tr>
<tr>
<td valign="top"> </td>
<td valign="top"> 150 mg (Day 5)</td>
<td align="center" valign="top"> 68 (18)</td>
<td align="center" valign="top"> 73 (9)</td>
<td align="center" valign="top"> 74 (14)</td>
<td align="center" valign="top"> 61 (14)</td>
</tr>
<tr>
<td valign="top"> VASP-PRI (%) <footnote id="FOOT_7368">Vasodilator-stimulated phosphoprotein – platelet reactivity index; smaller value indicates greater platelet inhibition</footnote>
</td>
<td valign="top"> 300 mg (24 h)</td>
<td align="center" valign="top"> 73 (12)</td>
<td align="center" valign="top"> 68 (16)</td>
<td align="center" valign="top"> 78 (12)</td>
<td align="center" valign="top"> 91 (12)</td>
</tr>
<tr>
<td valign="top"> </td>
<td valign="top"> 600 mg (24 h)</td>
<td align="center" valign="top"> 51 (20)</td>
<td align="center" valign="top"> 48 (20)</td>
<td align="center" valign="top"> 56 (26)</td>
<td align="center" valign="top"> 85 (14)</td>
</tr>
<tr>
<td valign="top"> </td>
<td valign="top"> 75 mg (Day 5)</td>
<td align="center" valign="top"> 40 (9)</td>
<td align="center" valign="top"> 39 (14)</td>
<td align="center" valign="top"> 50 (16)</td>
<td align="center" valign="top"> 83 (13)</td>
</tr>
<tr>
<td valign="top"> </td>
<td valign="top"> 150 mg (Day 5)</td>
<td align="center" valign="top"> 20 (10)</td>
<td align="center" valign="top"> 24 (10)</td>
<td align="center" valign="top"> 29 (11)</td>
<td align="center" valign="top"> 61 (18)</td>
</tr>
</tbody>
</table>